These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24375941)

  • 1. Results of the citalopram to enhance cognition in Huntington disease trial.
    Beglinger LJ; Adams WH; Langbehn D; Fiedorowicz JG; Jorge R; Biglan K; Caviness J; Olson B; Robinson RG; Kieburtz K; Paulsen JS
    Mov Disord; 2014 Mar; 29(3):401-5. PubMed ID: 24375941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.
    Nyth AL; Gottfries CG; Lyby K; Smedegaard-Andersen L; Gylding-Sabroe J; Kristensen M; Refsum HE; Ofsti E; Eriksson S; Syversen S
    Acta Psychiatr Scand; 1992 Aug; 86(2):138-45. PubMed ID: 1529737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
    Zisook S; Kasckow JW; Golshan S; Fellows I; Solorzano E; Lehman D; Mohamed S; Jeste DV
    J Clin Psychiatry; 2009 Apr; 70(4):562-71. PubMed ID: 19192468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease.
    Beglinger LJ; Adams WH; Fiedorowicz JG; Duff K; Langbehn D; Biglan K; Caviness J; Olson B; Paulsen JS
    J Huntingtons Dis; 2015; 4(3):251-60. PubMed ID: 26444022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial.
    Ghaemi SN; Whitham EA; Vohringer PA; Barroilhet SA; Amerio A; Sverdlov O; Patkar AA
    J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
    Lavretsky H; Reinlieb M; St Cyr N; Siddarth P; Ercoli LM; Senturk D
    Am J Psychiatry; 2015 Jun; 172(6):561-9. PubMed ID: 25677354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
    Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
    Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.
    Como PG; Rubin AJ; O'Brien CF; Lawler K; Hickey C; Rubin AE; Henderson R; McDermott MP; McDermott M; Steinberg K; Shoulson I
    Mov Disord; 1997 May; 12(3):397-401. PubMed ID: 9159735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
    Mendels J; Kiev A; Fabre LF
    Depress Anxiety; 1999; 9(2):54-60. PubMed ID: 10207659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease.
    Beglinger LJ; Adams WH; Paulson H; Fiedorowicz JG; Langbehn DR; Duff K; Leserman A; Paulsen JS
    J Clin Psychopharmacol; 2009 Oct; 29(5):484-7. PubMed ID: 19745649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in cognitive functioning following acute antidepressant treatment in late-life depression.
    Culang ME; Sneed JR; Keilp JG; Rutherford BR; Pelton GH; Devanand DP; Roose SP
    Am J Geriatr Psychiatry; 2009 Oct; 17(10):881-8. PubMed ID: 19916207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease.
    Smith MM; Mills JA; Epping EA; Westervelt HJ; Paulsen JS;
    Neuropsychology; 2012 Sep; 26(5):664-9. PubMed ID: 22846033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.
    Kloberg A; Constantinescu R; Nilsson MK; Carlsson ML; Carlsson A; Wahlström J; Haghighi S
    Acta Neuropsychiatr; 2014 Oct; 26(5):298-306. PubMed ID: 25241758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
    Gelderblom H; Wüstenberg T; McLean T; Mütze L; Fischer W; Saft C; Hoffmann R; Süssmuth S; Schlattmann P; van Duijn E; Landwehrmeyer B; Priller J
    PLoS One; 2017; 12(3):e0173872. PubMed ID: 28323838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
    Petersen JZ; Schmidt LS; Vinberg M; Jørgensen MB; Hageman I; Ehrenreich H; Knudsen GM; Kessing LV; Miskowiak KW
    Trials; 2018 Nov; 19(1):611. PubMed ID: 30400939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.
    Lepola UM; Wade AG; Leinonen EV; Koponen HJ; Frazer J; Sjödin I; Penttinen JT; Pedersen T; Lehto HJ
    J Clin Psychiatry; 1998 Oct; 59(10):528-34. PubMed ID: 9818634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.